| Market Cap | 475.22M | P/E | - | EPS this Y | 28.00% | Ern Qtrly Grth | - |
| Income | -206M | Forward P/E | -2.92 | EPS next Y | 57.10% | 50D Avg Chg | 15.00% |
| Sales | - | PEG | -0.02 | EPS past 5Y | - | 200D Avg Chg | -5.00% |
| Dividend | N/A | Price/Book | 1.69 | EPS next 5Y | 26.70% | 52W High Chg | -37.00% |
| Recommedations | 2.90 | Quick Ratio | 3.43 | Shares Outstanding | 88.85M | 52W Low Chg | 66.00% |
| Insider Own | 2.33% | ROA | -49.29% | Shares Float | 59.22M | Beta | 1.15 |
| Inst Own | 88.10% | ROE | -121.54% | Shares Shorted/Prior | 1.96M/2.31M | Price | 5.49 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,022,683 | Target Price | 2.77 |
| Oper. Margin | - | Earnings Date | Nov 11 | Volume | 705,580 | Change | -1.08% |
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
| JMP Securities | Market Outperform | Sep 26, 24 |
| Jefferies | Hold | Jul 18, 24 |
| JMP Securities | Market Outperform | Jun 26, 24 |
| Cantor Fitzgerald | Neutral | Jun 20, 24 |
| JMP Securities | Market Outperform | Jan 17, 24 |
| Barclays | Underweight | Jan 17, 24 |
| Jefferies | Hold | Jan 17, 24 |
| William Blair | Outperform | Dec 18, 23 |
| JMP Securities | Market Outperform | Nov 28, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Tomasi Adam | President and COO President and COO | Jun 07 | Sell | 91.15 | 3,129 | 285,208 | 150,707 | 06/07/21 |
| RASMUSSEN HENRIK S MD | Chief Medical Office.. Chief Medical Officer | Jun 04 | Sell | 89.6 | 2,435 | 218,176 | 98,550 | 06/04/21 |
| Alexander Robert | Chief Executive Offi.. Chief Executive Officer | May 19 | Option | 0.69 | 43,550 | 30,049 | 259,912 | 05/19/21 |
| Alexander Robert | Chief Executive Offi.. Chief Executive Officer | May 19 | Sell | 100.31 | 43,550 | 4,368,500 | 245,395 | 05/19/21 |
| Tomasi Adam | President and COO President and COO | May 13 | Option | 0.69 | 60,000 | 41,400 | 173,126 | 05/13/21 |
| Tomasi Adam | President and COO President and COO | May 13 | Sell | 97.68 | 60,000 | 5,860,800 | 153,126 | 05/13/21 |
| Tomasi Adam | President, COO and C.. President, COO and CFO | Apr 14 | Option | 0.69 | 60,000 | 41,400 | 173,126 | 04/14/21 |
| Tomasi Adam | President, COO and C.. President, COO and CFO | Apr 14 | Sell | 105.08 | 60,000 | 6,304,800 | 153,126 | 04/14/21 |
| RASMUSSEN HENRIK S MD | Chief Medical Office.. Chief Medical Officer | Apr 06 | Sell | 113.05 | 50,000 | 5,652,500 | 101,819 | 04/06/21 |
| RASMUSSEN HENRIK S MD | Chief Medical Office.. Chief Medical Officer | Apr 06 | Option | 1.16 | 50,000 | 58,000 | 121,819 | 04/06/21 |
| MCKEARN JOHN P | Director Director | Mar 30 | Sell | 115 | 7,439 | 855,485 | 1,200 | 03/30/21 |
| JANNEY DANIEL | Director Director | Mar 30 | Sell | 115.55 | 17,308 | 1,999,939 | 56,293 | 03/30/21 |
| JANNEY DANIEL | Director Director | Mar 24 | Sell | 119.84 | 13,148 | 1,575,656 | 73,601 | 03/24/21 |
| NOHRA GUY P | 10% Owner 10% Owner | Mar 08 | Sell | 111.33 | 25,768 | 2,868,751 | 03/08/21 | |
| MORE ROBERT J | Other Other | Mar 05 | Sell | 114.61 | 32,554 | 3,731,014 | 03/05/21 | |
| Tomasi Adam | President, COO and C.. President, COO and CFO | Mar 03 | Sell | 113.56 | 3,189 | 362,143 | 153,126 | 03/03/21 |
| RASMUSSEN HENRIK S MD | Chief Medical Office.. Chief Medical Officer | Mar 03 | Option | 1.16 | 60,000 | 69,600 | 125,087 | 03/03/21 |
| RASMUSSEN HENRIK S MD | Chief Medical Office.. Chief Medical Officer | Mar 03 | Sell | 115.95 | 61,952 | 7,183,334 | 105,087 | 03/03/21 |
| Walker Paul Edward | Director Director | Jan 04 | Sell | 141.66 | 103,415 | 14,649,769 | 2,163,260 | 01/04/21 |